Peptide Knowledge Base · Metabolic

Tirzepatide: what it is, what the evidence says, and its real status

The newest, most effective molecule in the metabolic class, with grade-A randomized human data behind it.

Can you actually get it?

Plain-English verdict: Available.

Regulatory status: 503A / shortage-exception pathway.

How does Tirzepatide work?

A dual agonist at both GIP and GLP-1 receptors, amplifying satiety and glycemic effects beyond a GLP-1 alone.

What it does — and what it does not do

What it does: Supports the largest average weight loss and metabolic improvement seen in randomized trials to date.

What it does not do: It is not a guaranteed result and not a substitute for the habits that keep the loss; compounded forms are not FDA-approved.

How honest is the evidence?

Evidence grade A — Strong human evidence.

large randomized controlled trials (SURMOUNT / SURPASS)

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Head-to-head long-term outcome data is still maturing; compounded-formulation specifics differ from the studied branded product.

WADA status: Not prohibited.

How it is taken

What the literature reports: weekly subcutaneous, titrated. Educational only, never an instruction to self-administer.

Who should not take it

Personal/family history of medullary thyroid carcinoma or MEN-2; pregnancy. GI tolerability is dose-dependent.

Sources

Jastreboff et al., SURMOUNT-1 (NEJM 2022) · FDA labeling (Zepbound/Mounjaro)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 16, 2026 · Peptós.LIFE · Not medical advice.